Technology | November 12, 2012

Volpara breast density measurement software provides an objective, reproducible measurement of breast density designed to improve early detection among women with dense breasts. It is used by radiologists to objectively assess density and help evaluate who might benefit from additional screening. It automatically generates objective measurement of volumetric breast density values under the Volpara Density Grade (VDG), a refined grading system which correlates with the American College of Radiology (ACR) BIRADS density grading classifications. It is U.S. Food and Drug Administration- (FDA-)cleared for all digital mammography (DM) units.

For more information: www.volparadensity.com


Related Content

News | Breast Imaging

Aug. 13, 2026 – Perimeter Medical Imaging AI recently announced that Intermountain Health, the largest nonprofit health ...

Time August 14, 2026
arrow
News | Breast Imaging

Aug. 3, 2026 — QT Imaging Holdings, is advancing the direct U.S. commercial strategy for its Breast Acoustic CT Scanner ...

Time August 04, 2026
arrow
News | Breast Imaging

Aug. 3, 2026 — GE HealthCare has launched Invenia ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue, a ...

Time August 03, 2026
arrow
News | Breast Imaging

July 30, 2026 — DeepHealth, Inc. has received FDA 510(k) clearance for DeepHealth Breast Ultrasound1, an AI-powered ...

Time July 31, 2026
arrow
News | Breast Imaging

July 7, 2026 — QT Imaging Holdings, Inc. recently announced it has successfully completed its first routine inspection ...

Time July 07, 2026
arrow
News | MRI Breast

July 2, 2026 – Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool which ...

Time July 02, 2026
arrow
News | Mammography

June 30, 2026 — The Food and Drug Administration has cleared new contrast-enhanced mammography (CEM) and CEM biopsy ...

Time June 30, 2026
arrow
News | Mammography

June 23, 2026 — Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer ...

Time June 24, 2026
arrow
News

May 21, 2026 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 22, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
Subscribe Now